Mineralys Therapeutics Completes Target Enrollment In Pivotal Advance-HTN Trial Of Lorundrostat For The Treatment Of Hypertension
Portfolio Pulse from Benzinga Newsdesk
Mineralys Therapeutics has completed target enrollment for its pivotal Advance-HTN trial of lorundrostat for hypertension treatment. Topline data is expected in Q1 2025, with a virtual event scheduled for October 30th to discuss the trial and unmet needs in hypertension.

September 25, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mineralys Therapeutics has reached its enrollment target for the Advance-HTN trial, a key milestone in developing lorundrostat for hypertension. Topline data is anticipated in Q1 2025, which could significantly impact the company's stock price.
Completing enrollment in a pivotal trial is a significant milestone for a clinical-stage biotech company. The anticipation of topline data in Q1 2025 suggests potential positive developments, which could drive investor interest and positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100